Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 2153-2158

  Wang, Liang ^a   Liu, Panpan ^a   Chen, Xiaoqin ^a   Geng, Qirong ^a   Lu, Yue ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Diffuse large B cell lymphoma; Immunochemotherapy; Neuron specific enolase; Non germinal center B cell like subtype; Overall survival

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; NEURON SPECIFIC ENOLASE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NON GERMINAL CENTER B CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; LUMINESCENT MEASUREMENTS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHOPYRUVATE HYDRATASE; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 84872821770     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0049-z     Document Type: Article

References (20)

1. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimes for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328: 1002-6.
2. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26:3603-13.
3. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-11.
4. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103: 275-82.
5. Xia ZG, Xu ZZ, Zhao WL, et al. The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment. Ann Hematol. 2010;89:171-7.
6. Fang C, Xu W, Li JY. A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma. Ann Hematol. 2010;89:1107-13.
7. Shizusawa T, Shibayama H, Murata S, et al. The expression of anamorsin in diffuse large B cell lymphoma: possible prognostic biomarker for low IPI patients. Leuk Lymphoma. 2008;49(1): 113-21.
8. Tapia FJ, Polak JM, Barbosa AJ, et al. Neuron-specific enolase is produced by neuroendocrine tumours. Lancet. 1981;1:808-11.
9. Nakatsuka S, Nishiu M, Tomita Y, et al. Enhanced expression of neuron-specific enolase (NSE) in pyothorax-associated lymphoma (PAL). Jpn J Cancer Res. 2002;93:411-6.
10. Delsol G. The 2008 WHO lymphoma classification. Ann Pathol. 2008;28(Spec No 1):S20-4.
11. Miller AA, Salewski E. Prospects for pirarubicin. Med Pediatr Oncol. 1994;22:261-8.
12. Tsurumi H, Yamada T, Sawada M, et al. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol. 2004;130:107-13.
13. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
14. Li JM, Wang L, Shen Y, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Ann Hematol. 2007;86:639-45.
15. Berglund M, Thunberg U, Amini RM, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol. 2005;18:1113-20.
16. Shiozawa E, Yamochi-Onizuka T, Takimoto M, Ota H. The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res. 2007;31:1579-83.
17. Nemeth J, Galian A, Mikol J. Béatrix Cochand-Priollet, Michel Wassef and Anne Lavergne. Neuron-specific enolase and malignant lymphomas (23 cases). Virchows Arch A Pathol Anat Histopathol. 1987;412:89-93.
18. Moro MA, De Alba J, Cardenas A, et al. Mechanisms of the neuroprotective effect of aspirin after oxygen and glucose derivation in rat forebrain slices. Neuropharmacology. 2000;39: 1309-18.
19. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194(12):1861-74.
20. Fujiwara H, Arima N, Ohtsubo H, et al. Clinical significance of serum neuron-specific enolase in patients with adult T-cell leukemia. Am J Hematol. 2002;71:80-4.